Inhibition of Breast Tumour Growth with Intravenously Administered PRKCA siRNA- and PTEN Tumour Suppressor Gene-Loaded Carbonate Apatite Nanoparticles

Gene therapy aims to silence an oncogene through RNA interference, or replace abnormal tumour suppressor via gene augmentation. In this study, we intended interference for PRKCA and augmentation PTEN with a view reduce growth in mouse model of breast cancer. Inorganic carbonate apatite nanoparticles (CA NPs) were utilized deliver the synthetic siRNA purified gene-carrying plasmid DNA both vitro vivo. Effects siRNA- plasmid-loaded NPs on viability MCF-7, MDA-MB-231 4T1 cancer cells assessed by MTT assay. The cell data MCF-7 line demonstrated that combined delivery specific CA had additive effect significantly decrease cellular compared individual treatments. addition, observed similar pattern cumulative influence treatment triple negative line. Upon siRNA+PTEN NPs, remarkable phosphorylated form AKT protein PI3K/AKT pathway was Western blot, indicative diminished proliferative signal. Moreover, vivo study xenograft rate final volume reduced group received intravenous siRNA+NPs, plasmid+NPs. Our findings loaded into attenuated growth, suggesting their therapeutic potential